EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY-NC 3.0

Hematological Safety of Contezolid versus Linezolid in Stage 5 Chronic Kidney Disease: An Active-Comparator New-User Retrospective Cohort Study

Wenjun Zhang, Xinfeng Cai, Ruigang Hou, Jinlin Guo iD, Ying Ma, Jianbang Kang, Xingang Li iD

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s576881 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Wenjun Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China. Hauptthemen laut MEDLINE: Anemia, Anti-Bacterial Agents, Linezolid, Oxazolidinones. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Contezolid is a novel oxazolidinone antibiotic approved for treating Gram-positive bacterial infections. Unlike linezolid, it lacks myelosuppressive toxicity, a potential advantage in patients with renal failure who are prone to anemia. However, data on hematologic safety of contezolid in this population remains limited. This study evaluates the hematological effects of contezolid in patients with renal failure.

Methods

This two-center retrospective cohort study employed an active-comparator new-user design to compare the hematological safety of contezolid versus linezolid in patients with renal failure. The primary outcome was the impact of contezolid and linezolid on hemoglobin levels. The secondary outcomes included microbial eradication, clinical cure rate and adverse reaction. Propensity score matching and multivariate logistic regression were used to adjust for confounding factors.

Results

A total of 290 patients were enrolled, with 122 in the contezolid group and 168 in the linezolid group. Severe anemia occurred in 14.75% of patients receiving contezolid versus 46.43% with linezolid (P < 0.001). No significant differences in platelet count (P = 0.072), clinical cure rate (P = 0.878), procalcitonin levels (P = 0.432), or microbial eradication rates (P = 0.411) were observed between the contezolid and linezolid groups after treatment. Multivariate-adjusted logistic analysis further illustrated that, compared to contezolid, linezolid was associated with a higher risk of severe anemia (adjusted odds ratio: 2.29; 95% CI: 1.64-3.35), with a treatment duration cutoff of 7 days.

Conclusion

Compared with linezolid, contezolid was associated with a lower risk of clinically significant hemoglobin decline among patients with renal failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnemiaAnti-Bacterial AgentsLinezolidOxazolidinonesRenal Insufficiency, ChronicAgedFemaleHumansMaleMiddle AgedCohort StudiesHemoglobinsRetrospective Studies

Stichwörter der Autor:innen

contezolidhemoglobinlinezolidmyelosuppressionrenal failure

Substanzen

Anti-Bacterial AgentsHemoglobinsLinezolidOxazolidinones

Autor:innen und Institutionen

  • Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
  • Department of Pharmacy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, People…
  • The Fifth Clinical Medical College of Shanxi Medical University/Shanxi Provincial People's Hospital, Taiyuan, Shanxi, People's Republic of China.
  • State Institution of Drug Clinical Trials, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, People's Republic of China.
  • Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.

ORCID-Profile: Jinlin Guo, Xingang Li

Zitieren

APA

Zhang, W., Cai, X., Hou, R., Guo, J., Ma, Y., Kang, J., & Li, X. (2026). Hematological Safety of Contezolid versus Linezolid in Stage 5 Chronic Kidney Disease: An Active-Comparator New-User Retrospective Cohort Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s576881

Vancouver

Zhang W, Cai X, Hou R, Guo J, Ma Y, Kang J, et al. Hematological Safety of Contezolid versus Linezolid in Stage 5 Chronic Kidney Disease: An Active-Comparator New-User Retrospective Cohort Study. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s576881

BibTeX
@article{Zhang2026,
  author = {Zhang, Wenjun and Cai, Xinfeng and Hou, Ruigang and Guo, Jinlin and Ma, Ying and Kang, Jianbang and Li, Xingang},
  title = {Hematological Safety of Contezolid versus Linezolid in Stage 5 Chronic Kidney Disease: An Active-Comparator New-User Retrospective Cohort Study},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s576881}
}
Kostenlos starten →